Historical Overview (1938-2010)

The roots of our program lie in the Division of Hematology, which was founded at Washington University in 1938 by Dr. Carl V. Moore. The Division of Hematology encompassed the field of oncology until 1994, when a separate Division of Oncology was established.


Virginia Minnich and Carl Moore at work (circa 1965)

Trainees are an integral part of both divisions. Since 1966, we have trained over 290 clinical fellows in hematology/oncology as well as numerous post-doctoral research fellows and graduate students. Many of our graduates pursue academic careers at major institutions; several, in fact, have joined our own faculty.

Our faculty have contributed significant knowledge to the fields of hematology and oncology. Examples include the discovery of how aspirin inhibits platelet function, full DNA sequences for AML and breast cancer, advances in gene therapy, and immunotherapy for melanoma.


The Hematology Division features subspecialists focusing on basic and clinical research in:

  • Hemostasis and thrombosis
  • Sickle cell disease
  • Cell signaling
  • Gene therapy
  • Protein trafficking
  • Myeloproliferative neoplasms


The Oncology Division features general oncologists as well as subspecialists focusing on basic and clinical research in:

  • Lung Cancer
    • Genetic analysis of non-small cell lung cancer
  • Head and Neck Cancer
    • Trop 2 as a predictive and prognostic biomarker
    • Novel induction chemotherapy regimens
    • Novel palliative chemotherapy/targeted therapy regimens
  • GI Cancers
    • Chemoresistance of pancreatic cancers
  • GU Cancers
    • Castrate-resistant prostate cancers
  • Melanoma
    • Dendritic cell-based vaccines
    • Adoptive T cell therapies
  • Sarcomas
    • Arginine succinate synthetase as a therapeutic agent
  • Brain Tumors
    • Vaccine trials in glioblastoma
  • Lymphomas
    • Novel phase 1, 2, 3 studies in indolent and aggressive lymphomas
    • Retrovirus-associated leukemias and lymphomas
    • Obesity and lymphoma
  • Leukemias
  • Myeloma
  • Bone marrow and stem cell transplantation
  • Breast Cancer
    • Genomics of breast cancer
    • Phosphoinositol-3-kinase pathway inhibitors
    • Phosphoproteomics and tyrosine kinases
    • Claudin-low breast cancer subtype
    • Mechanisms of tumor dissemination
  • Molecular Oncology
    • Human T cell leukemia virus and NFkB signaling
    • Epithelial-mesenchymal transition, cancer metastasis, gliomas
    • Molecular determinants of myeloid cell regulation of tumors
    • Arf and ribosome biogenesis
    • Bone metastases
    • Myeloma
    • DNA methyl transferases
  • Palliative Care